Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Chronic Myelocytic Leukemia - Pipeline Review, H1 2018, provides an overview of the Chronic Myelocytic Leukemia (Oncology) pipeline landscape.

This latest pipeline guide Chronic Myelocytic Leukemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 29, 24, 20 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 4, 10 and 3 molecules, respectively.

Chronic Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview
  3. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Development
  4. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment
  5. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development
  6. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles
  7. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects
  8. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products
  9. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones
  10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/7km9sz/chronic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs